Esperion Therapeutis.Inc. buy Quitte
Start price
20.01.16
/
50%
€14.56
Target price
21.07.16
€17.50
Performance (%)
-32.35%
End price
21.07.16
€9.85
Summary
This prediction ended on 21.07.16 with a price of €9.85. Massive losses of -32.35% were the result for the BUY prediction by Quitte. Quitte has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | -3.133% | -3.133% | 42.521% | -42.779% |
| iShares Core DAX® | 0.060% | 1.215% | 18.128% | 70.406% |
| iShares Nasdaq 100 | -3.065% | -0.519% | 2.080% | 103.787% |
| iShares Nikkei 225® | -2.094% | -3.066% | 11.655% | 45.417% |
| iShares S&P 500 | -1.657% | -0.069% | 1.103% | 64.908% |
Comments by Quitte for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Jammertal ade
irgendwann muss das was werden
(Laufzeit überschritten)